Stock Groups

Moderna receives full U.S. approval for COVID-19 vaccine -Breaking

by Mike Robinson

[ad_1]

© Reuters. This illustration, taken May 21st 2021 shows test tubes positioned in front of the Moderna logo. REUTERS/Dado Ruvic/Illustration

(Reuters) – Moderna (NASDAQ:) Inc on Monday announced that the U.S. Food and Drug Administration had given its COVID-19 vaccination for people aged 18 and older full approval

Moderna issued an emergency use authorization for the vaccine in December 2020. In August 2018, Moderna stated that it was now ready to file the necessary paperwork to approve the vaccine.

Pfizer (NYSE:), and BioNTech’s COVID-19 shot were approved in full by the United States government last year.

Moderna’s vaccine can be used in more than 70 countries. This includes Canada and the European Union.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]